keyword
MENU ▼
Read by QxMD icon Read
search

Biomarker AND parkinson's disease

keyword
https://www.readbyqxmd.com/read/29776865/gut-microbiota-in-patients-with-parkinson-s-disease-in-southern-china
#1
Aiqun Lin, Wenxia Zheng, Yan He, Wenli Tang, Xiaobo Wei, Rongni He, Wei Huang, Yuying Su, Yaowei Huang, Hongwei Zhou, Huifang Xie
INTRODUCTION: Accumulating evidence has revealed alterations in the communication between the gut and brain in patients with Parkinson's disease (PD), and previous studies have confirmed that alterations in the gut microbiome play an important role in the pathogenesis of numerous diseases, including PD. The aim of this study was to determine whether the faecal microbiome of PD patients in southern China differs from that of control subjects and whether the gut microbiome composition alters among different PD motor phenotypes...
May 16, 2018: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/29764386/parkinson-s-disease-diagnostic-observations-paddo-study-rationale-and-design-of-a-prospective-cohort-study-for-early-differentiation-of-parkinsonism
#2
Anouke van Rumund, Marjolein B Aerts, Rianne A J Esselink, Frederick J A Meijer, Marcel M Verbeek, Bastiaan R Bloem
BACKGROUND: Differentiation of Parkinson's disease (PD) from the various types of atypical parkinsonism (AP) such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), corticobasal syndrome (CBS) and vascular parkinsonism (VP), can be challenging, especially early in the disease course when symptoms overlap. A major unmet need in the diagnostic workup of these disorders is a diagnostic tool that differentiates the various disorders, preferably in the earliest disease stages when the clinical presentation is similar...
May 16, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29764353/non-motor-parkinson-disease-new-concepts-and-personalised-management
#3
Nataliya Titova, K Ray Chaudhuri
Most patients with Parkinson disease (PD) have non-motor symptoms (NMS), and on average these can range from four to 19 different symptoms. NMS dominate the prodromal phase of PD and some may serve as clinical biomarkers of PD. NMS can be dopaminergic, non-dopaminergic, of genetic origin or drug induced. Clinical assessment of NMS should include the NMS Questionnaire (completed by patients) for screening, as recommended by the International Parkinson and Movement Disorders Society and other international societies...
May 21, 2018: Medical Journal of Australia
https://www.readbyqxmd.com/read/29762036/biochemical-profiling-of-the-brain-and-blood-metabolome-in-a-mouse-model-of-prodromal-parkinson-s-disease-reveal-distinct-metabolic-profiles
#4
Stewart F Graham, Nowlen L Rey, Ali Yilmaz, Praveen Kumar, Zachary Madaj, Michael Maddens, Ray O Bahado-Singh, Katelyn Becker, Emily Schulz, Lindsay K Meyerdirk, Jennifer A Steiner, Jiyan Ma, Patrik Brundin
Parkinson's disease is the second most common neurodegenerative disease. In the vast majority of cases the origin is not genetic and the cause is not well understood, although progressive accumulation of α-synuclein aggregates appears central to the pathogenesis. Currently, treatments that slow disease progression are lacking and there are no robust biomarkers that can facilitate development of such treatments, or act as aids in early diagnosis. Therefore, we have defined metabolomic changes in the brain and serum in an animal model of prodromal Parkinson's disease...
May 15, 2018: Journal of Proteome Research
https://www.readbyqxmd.com/read/29758248/beneficial-effect-of-etazolate-on-depression-like-behavior-and-learning-and-memory-impairment-in-a-model-of-parkinson-s-disease
#5
Karem H Alzoubi, Enas Mokhemer, Amjad N Abuirmeileh
The aim of this study was to evaluate etazolate against depression-like behavior and, learning and memory impairment induced by 6- hydroxydopamine (6-OHDA) rat model of Parkinson's disease (PD). This aim was achieved through comparing 6-OHDA lesioned rats in the presence and absence of etazolate. The 6-OHDA was used to induce lesion as a model of PD. Etazolate was administered at a dose of 1 mg/kg/day for 14 days, starting 7 days after lesion induction. Apomorphine-induced rotation test was used to evaluate 6-OHDA-induced motor deficits, tail suspension test was used to assess depression-like symptoms, and the radial arms water maze (RAWM) was used to evaluate special learning and memory functions...
May 11, 2018: Behavioural Brain Research
https://www.readbyqxmd.com/read/29756231/susceptibility-mri-captures-nigral-pathology-in-patients-with-parkinsonian-syndromes
#6
Mechelle M Lewis, Guangwei Du, Jennifer Baccon, Amanda M Snyder, Ben Murie, Felicia Cooper, Christy Stetter, Lan Kong, Christopher Sica, Richard B Mailman, James R Connor, Xuemei Huang
BACKGROUND: Parkinsonisms are neurodegenerative disorders characterized pathologically by α-synuclein-positive (e.g., PD, diffuse Lewy body disease, and MSA) and/or tau-positive (e.g., PSP, cortical basal degeneration) pathology. Using R2* and quantitative susceptibility mapping, susceptibility changes have been reported in the midbrain of living parkinsonian patients, although the exact underlying pathology of these alterations is unknown. OBJECTIVE: The current study investigated the pathological correlates of these susceptibility MRI measures...
May 14, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29755728/combination-of-multifocal-electroretinogram-and-spectral-domain-oct-can-increase-diagnostic-efficacy-of-parkinson-s-disease
#7
Jiang Huang, Yi Li, Jianjiang Xiao, Qin Zhang, Guoxu Xu, Guanhui Wu, Tong Liu, Weifeng Luo
Background: The retinal changes have been identified in morphology and function in Parkinson's disease (PD). However, the controversial results suggest that it is incredible that only using a single method for testing retinal change to evaluate Parkinson's disease. The aim of this study was to assess retinal changes and increase the diagnostic efficacy of Parkinson's disease with a combination of multifocal electroretinogram (mf-ERG) and spectral domain optical coherence tomography (SD-OCT) examinations...
2018: Parkinson's Disease
https://www.readbyqxmd.com/read/29755341/plasma-biomarkers-differentiate-parkinson-s-disease-from-atypical-parkinsonism-syndromes
#8
Chin-Hsien Lin, Shieh-Yueh Yang, Herng-Er Horng, Che-Chuan Yang, Jen-Jie Chieh, Hsin-Hsien Chen, Bing-Hsien Liu, Ming-Jang Chiu
Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples ( n = 204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or frontotemporal dementia (FTD) with parkinsonism (FTD-P) or without parkinsonism...
2018: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/29742117/tubulin-and-tau-possible-targets-for-diagnosis-of-parkinson-s-and-alzheimer-s-diseases
#9
Mohamed Salama, Ali Shalash, Alshimaa Magdy, Marianne Makar, Tamer Roushdy, Mahmoud Elbalkimy, Hanan Elrassas, Passent Elkafrawy, Wael Mohamed, Mohamed B Abou Donia
Neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by progressive neuronal loss and pathological accumulation of some proteins. Developing new biomarkers for both diseases is highly important for the early diagnosis and possible development of neuro-protective strategies. Serum antibodies (AIAs) against neuronal proteins are potential biomarkers for AD and PD that may be formed in response to their release into systemic circulation after brain damage...
2018: PloS One
https://www.readbyqxmd.com/read/29737566/phosphorylated-%C3%AE-synuclein-in-the-retina-is-a-biomarker-of-parkinson-s-disease-pathology-severity
#10
Isabel Ortuño-Lizarán, Thomas G Beach, Geidy E Serrano, Douglas G Walker, Charles H Adler, Nicolás Cuenca
BACKGROUND: PD patients often have visual alterations, for example, loss of visual acuity, contrast sensitivity or motion perception, and diminished electroretinogram responses. PD pathology is mainly characterized by the accumulation of pathological α-synuclein deposits in the brain, but little is known about how synucleinopathy affects the retina. OBJECTIVE: To study the correlation between α-synuclein deposits in the retina and brain of autopsied subjects with PD and incidental Lewy body disease...
May 8, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29736227/molecular-mechanisms-of-omega-3-fatty-acids-in-the-migraine-headache
#11
REVIEW
Neda Soveyd, Mina Abdolahi, Sama Bitarafan, Abbas Tafakhori, Payam Sarraf, Mansoureh Togha, Ali Asghar Okhovat, Mahsa Hatami, Mohsen Sedighiyan, Mahmoud Djalali, Niyaz Mohammadzadeh Honarvar
Migraine is a common chronic inflammatory neurological disease with the progressive and episodic course. Much evidence have shown a role of inflammation in the pathogenesis of migraine. Omega-3 fatty acids are an important components of cell membranes phospholipids. The intake of these fatty acids is related to decrease concentration of C-reactive protein (CRP), proinflammatory eicosanoids, cytokines, chemokines and other inflammation biomarkers. Many of clinical trials have shown the beneficial effect of dietary supplementation with omega-3 fatty acids in inflammatory and autoimmune diseases in human, including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), multiple sclerosis (MS) and migraine headaches...
October 7, 2017: Iranian Journal of Neurology
https://www.readbyqxmd.com/read/29729620/volumetric-brain-analysis-as-a-predictor-of-a-worse-cognitive-outcome-in-parkinson-s-disease
#12
Luiz Felipe Vasconcellos, João Santos Pereira, Marcelo Adachi, Denise Greca, Manuela Cruz, Ana Lara Malak, Helenice Charchat-Fichman
Cognitive impairment in Parkinson's disease (PD) results in significant morbidity and mortality being early diagnosis essential. Identification of patients who are at higher risk of developing cognitive impairment based only on clinical data is not sufficient. To this end, magnetic resonance imaging (MRI) with automatic segmentation, such as FreeSurfer, could be a useful tool with high accuracy because it has histological validation. OBJECTIVES: The objective of this study was to evaluate clinical, neuropsychological and FreeSurfer variables that may be related to worse cognitive outcomes over 18 months in PD patients compared with controls...
April 27, 2018: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29727475/subthalamic-nucleus-deep-brain-stimulation-evokes-resonant-neural-activity
#13
Nicholas C Sinclair, Hugh J McDermott, Kristian J Bulluss, James B Fallon, Thushara Perera, San San Xu, Peter Brown, Wesley Thevathasan
Deep brain stimulation (DBS) is a rapidly expanding treatment for neurological and psychiatric conditions; however, a target-specific biomarker is required to optimize therapy. Here, we show that DBS evokes a large-amplitude resonant neural response focally in the subthalamic nucleus. This response is greatest in the dorsal region (the clinically optimal stimulation target for Parkinson disease), coincides with improved clinical performance, is chronically recordable, and is present under general anesthesia...
May 4, 2018: Annals of Neurology
https://www.readbyqxmd.com/read/29710734/evidence-of-neurobiological-changes-in-the-presymptomatic-pink1-knockout-rat
#14
Craig F Ferris, Thomas R Morrison, Sade Iriah, Samantha Malmberg, Praveen Kulkarni, Jochen C Hartner, Malav Trivedi
BACKGROUND: Genetic models of Parkinson's disease (PD) coupled with advanced imaging techniques can elucidate neurobiological disease progression, and can help identify early biomarkers before clinical signs emerge. PTEN-induced putative kinase 1 (PINK1) helps protect neurons from mitochondrial dysfunction, and a mutation in the associated gene is a risk factor for recessive familial PD. The PINK1 knockout (KO) rat is a novel model for familial PD that has not been neuroradiologically characterized for alterations in brain structure/function, alongside behavior, prior to 4 months of age...
April 25, 2018: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/29707617/detection-of-endogenous-s1292-lrrk2-autophosphorylation-in-mouse-tissue-as-a-readout-for-kinase-activity
#15
Jillian H Kluss, Melissa M Conti, Alice Kaganovich, Aleksandra Beilina, Heather L Melrose, Mark R Cookson, Adamantios Mamais
Parkinson's disease-linked mutations in LRRK2 enhance the kinase activity of the protein, therefore targeting LRRK2 kinase activity is a promising therapeutic approach. Phosphorylation at S935 of LRRK2 and of its Rab GTPase substrates have proven very useful biomarkers to monitor its kinase activity. Complementary to these approaches autophosphorylation of LRRK2 can be used as a direct kinase activity readout but to date detection of autophosphorylation at endogenous levels in vivo has been limited. We developed a fractionation-based enrichment method to successfully detect endogenous S1292 LRRK2 autophosphorylation in mouse tissues and highlight S1292 as a physiological readout candidate for LRRK2 kinase activity in vivo...
2018: NPJ Parkinson's Disease
https://www.readbyqxmd.com/read/29707120/mirna-based-signatures-in-cerebrospinal-fluid-as-potential-diagnostic-tools-for-early-stage-parkinson-s-disease
#16
Marcia Cristina T Dos Santos, Miguel Arturo Barreto-Sanz, Bruna Renata S Correia, Rosie Bell, Catherine Widnall, Luis Tosar Perez, Caroline Berteau, Claudia Schulte, Dieter Scheller, Daniela Berg, Walter Maetzler, Pedro A F Galante, Andre Nogueira da Costa
Parkinson's Disease is the second most common neurodegenerative disorder, affecting 1-2% of the elderly population. Its diagnosis is still based on the identification of motor symptoms when a considerable number of dopaminergic neurons are already lost. The development of translatable biomarkers for accurate diagnosis at the earliest stages of PD is of extreme interest. Several microRNAs have been associated with PD pathophysiology. Consequently, microRNAs are emerging as potential biomarkers, especially due to their presence in Cerebrospinal Fluid and peripheral circulation...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29705185/plasma-%C3%AE-synuclein-and-cognitive-impairment-in-the-parkinson-s-associated-risk-syndrome-a-pilot-study
#17
Hua Wang, Anzari Atik, Tessandra Stewart, Carmen Ginghina, Patrick Aro, Kathleen F Kerr, John Seibyl, Danna Jennings, Poul Henning Jensen, Kenneth Marek, Min Shi, Jing Zhang
Plasma total and nervous system derived exosomal (NDE) α-synuclein have been determined as potential biomarkers of Parkinson's disease (PD). To explore the utility of plasma α-synuclein in the prodromal phase of PD, plasma total and NDE α-synuclein were evaluated in baseline and 2-year follow-up samples from 256 individuals recruited as part of the Parkinson's Associated Risk Syndrome (PARS) study. The results demonstrated that baseline and longitudinal increases in total α-synuclein predicted progression of cognitive decline in hyposmic individuals with dopamine transporter (DAT) binding reduction...
April 26, 2018: Neurobiology of Disease
https://www.readbyqxmd.com/read/29702348/exploring-diagnosis-and-imaging-biomarkers-of-parkinson-s-disease-via-iterative-canonical-correlation-analysis-based-feature-selection
#18
Luyan Liu, Qian Wang, Ehsan Adeli, Lichi Zhang, Han Zhang, Dinggang Shen
Parkinson's disease (PD) is a neurodegenerative disorder that progressively hampers the brain functions and leads to various movement and non-motor symptoms. However, it is difficult to attain early-stage PD diagnosis based on the subjective judgment of physicians in clinical routines. Therefore, automatic and accurate diagnosis of PD is highly demanded, so that the corresponding treatment can be implemented more appropriately. In this paper, we focus on finding the most discriminative features from different brain regions in PD through T1-weighted MR images, which can help the subsequent PD diagnosis...
April 4, 2018: Computerized Medical Imaging and Graphics: the Official Journal of the Computerized Medical Imaging Society
https://www.readbyqxmd.com/read/29701787/nucleus-basalis-of-meynert-degeneration-precedes-and-predicts-cognitive-impairment-in-parkinson-s-disease
#19
Jonathan Schulz, Gennaro Pagano, Juan Alberto Fernández Bonfante, Heather Wilson, Marios Politis
Currently, no reliable predictors of cognitive impairment in Parkinson's disease exist. We hypothesized that microstructural changes at grey matter T1-weighted MRI and diffusion tensor imaging in the cholinergic system nuclei and associated limbic pathways underlie cognitive impairment in Parkinson's disease. We performed a cross-sectional comparison between patients with Parkinson's disease with and without cognitive impairment. We also performed a longitudinal 36-month follow-up study of cognitively intact Parkinson's disease patients, comparing patients who remained cognitively intact to those who developed cognitive impairment...
May 1, 2018: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/29701258/evaluation-of-smartphone-based-testing-to-generate-exploratory-outcome-measures-in-a-phase-1-parkinson-s-disease-clinical-trial
#20
Florian Lipsmeier, Kirsten I Taylor, Timothy Kilchenmann, Detlef Wolf, Alf Scotland, Jens Schjodt-Eriksen, Wei-Yi Cheng, Ignacio Fernandez-Garcia, Juliane Siebourg-Polster, Liping Jin, Jay Soto, Lynne Verselis, Frank Boess, Martin Koller, Michael Grundman, Andreas U Monsch, Ronald B Postuma, Anirvan Ghosh, Thomas Kremer, Christian Czech, Christian Gossens, Michael Lindemann
BACKGROUND: Ubiquitous digital technologies such as smartphone sensors promise to fundamentally change biomedical research and treatment monitoring in neurological diseases such as PD, creating a new domain of digital biomarkers. OBJECTIVES: The present study assessed the feasibility, reliability, and validity of smartphone-based digital biomarkers of PD in a clinical trial setting. METHODS: During a 6-month, phase 1b clinical trial with 44 Parkinson participants, and an independent, 45-day study in 35 age-matched healthy controls, participants completed six daily motor active tests (sustained phonation, rest tremor, postural tremor, finger-tapping, balance, and gait), then carried the smartphone during the day (passive monitoring), enabling assessment of, for example, time spent walking and sit-to-stand transitions by gyroscopic and accelerometer data...
April 27, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
keyword
keyword
25299
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"